TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19851113

Group type: EXPERIMENTAL
Intervention: Virtual fibreoptic intubation (VFI) software, self-training until competency, evaluated 2 weeks later.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group taught conventionally by an expert bronchoscopist with a 1 h lecture.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: VFI group (I)
Number of subjects: 42
Study: 17607121

Group type: EXPERIMENTAL
Intervention: Paclitaxel (110 mg/m2 on day 1), topotecan (1.5 mg/m2 on days 2-4), etoposide (160 mg/m2 on days 5-7 every 21 days) followed by chest irradiation to 70 Gy and carboplatin (AUC 5 on day 1) and etoposide (100 mg/m2 on days 1-3 every 21 days) without filgrastim for three cycles.
Number of subjects: 65
Study: 15983290

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg/d)
Number of subjects: 31512

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg/d)
Number of subjects: 31512

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 31512
Study: 12270981

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily, n=11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-arginine (100 mg/kg/30 min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-arginine (500 mg/kg/30 min)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All groups (including hypercholesterolaemic patients, young healthy, and older healthy controls)
Number of subjects: 21
Study: 10097934

Group type: EXPERIMENTAL
Intervention: nisoldipine (20-40 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: lisinopril (10-20 mg/day)
Number of subjects: 50
Study: 8947977

Group type: COMPARATOR
Intervention: Caffeine with water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine with grapefruit juice (GFJ)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine with multiple GFJ doses
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Caffeine with GFJ
Number of subjects: 10
Study: 1755386

Group type: EXPERIMENTAL
Intervention: Nursing home care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-stay geriatric ward care
Number of subjects: 0
Study: 7007357

Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 46
Study: 31615021

Group type: EXPERIMENTAL
Intervention: Higher preconception vegetable intake (per 10 g/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Higher preconception fruit intake (per 10 g/day)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Higher preconception intake of sugary drinks
Number of subjects: 46
Study: 28403943

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (250,000 IU vitamin D3 bolus)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 26289822

Group type: EXPERIMENTAL
Intervention: Emergency department physician diagnosis
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Disagreement between emergency department diagnosis and adjudication committee diagnosis
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Agreement between emergency department diagnosis and adjudication committee diagnosis
Number of subjects: 477
Study: 24436240

Group type: EXPERIMENTAL
Intervention: Mild hypothermia (35°C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard stroke unit care (Control)
Number of subjects: 36
Study: 22617844

Group type: EXPERIMENTAL
Intervention: HibMenCY-TT coadministered with MMR and VAR
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Hib conjugate vaccine coadministered with MMR and VAR
Number of subjects: 1257
Study: 21050401

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 0
Study: 17560680

Group type: EXPERIMENTAL
Intervention: Noradrenalin (0.1-0.7 microg/kg/min) and albumin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Terlipressin (1-2 mg/4h) and albumin
Number of subjects: 22
Study: 15561446

Group type: EXPERIMENTAL
Intervention: Substance use reduction (SR)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Activity increase (AI)
Number of subjects: 133

Group type: COMPARATOR
Intervention: No-change control
Number of subjects: 133
Study: 14658376

Group type: EXPERIMENTAL
Intervention: 305C (females)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 305B (males)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of reverse dives
Number of subjects: 45
Study: 9474615

Group type: EXPERIMENTAL
Intervention: 800 mg of oral acyclovir twice daily (1600 mg/day) for 3 to 7 days before sun exposure
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 8351436

Group type: EXPERIMENTAL
Intervention: Fenestrated sheath
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ordinary nonfenestrated sheath
Number of subjects: 153
Study: 3565338

Group type: COMPARATOR
Intervention: Psyllium (7.2 g/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Psyllium plus senna (6.5 + 1.5 g/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both laxatives
Number of subjects: 42
Study: 30477852

Group type: EXPERIMENTAL
Intervention: 5-minute facial massage roller on the right cheek
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 5-week daily use of facial massage roller on the right cheek
Number of subjects: 26
Study: 27696929

Group type: EXPERIMENTAL
Intervention: Psychoeducation sessions (2 sessions per week for 1 month, total of 8 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 24700490

Group type: EXPERIMENTAL
Intervention: Tafenoquine 1200 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tafenoquine 300 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tafenoquine 600 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 22435835

Group type: EXPERIMENTAL
Intervention: Nurse-run, telephone-based outreach intervention
Number of subjects: 762

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 762
Study: 20609641

Group type: EXPERIMENTAL
Intervention: Minnesota Code (MC)
Number of subjects: 64597

Group type: EXPERIMENTAL
Intervention: Novacode (NC)
Number of subjects: 64597

Group type: EXPERIMENTAL
Intervention: Major ST-T abnormalities (MC or NC)
Number of subjects: 64597
Study: 17884359

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (high-dose)
Number of subjects: 8658

Group type: COMPARATOR
Intervention: Moderate statin therapy (standard-dose)
Number of subjects: 8658
Study: 16130584

Group type: EXPERIMENTAL
Intervention: Bowel cancer and physical activity message (n = 141)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Heart disease and physical activity message (n = 140)
Number of subjects: 281
Study: 11877613

Group type: EXPERIMENTAL
Intervention: Fibrillated cartilage (group B)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Eburnated bone (group A)
Number of subjects: 73
Study: 10440463

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 0
Study: 8950071

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg, given orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1742248

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg (Indocid)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid 100 mg (Surgam)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium acetylsalicylate 1 g (Catalgine)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 16
Study: 7081727

Group type: COMPARATOR
Intervention: Intravenous morphine sulfate 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine 10 mg
Number of subjects: 10
Study: 31531525

Group type: EXPERIMENTAL
Intervention: Tirofiban combined with Solitaire AB stent
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thrombectomy with cerebral artery stents alone
Number of subjects: 120
Study: 28316174

Group type: EXPERIMENTAL
Intervention: ivabradine (starting dose 5 mg bid, uptitrated to 7.5 mg bid)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 225

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study: 25888726

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) training
Number of subjects: 232

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 232
Study: 24379072

Group type: EXPERIMENTAL
Intervention: Group T (TIVA with propofol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group C (Inhalation anesthesia with desflurane)
Number of subjects: 40
Study: 20598710

Group type: EXPERIMENTAL
Intervention: rEEG-guided pharmacotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (venlafaxine XR or STAR*D regimen)
Number of subjects: 114
Study: 19972661

Group type: EXPERIMENTAL
Intervention: Baby Wordsworth DVD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no DVD)
Number of subjects: 100
Study: 17511752

Group type: EXPERIMENTAL
Intervention: Daily estimation assessment procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment batteries
Number of subjects: 0
Study: 14747225

Group type: EXPERIMENTAL
Intervention: Caiapo (4 g once daily for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11427767

Group type: EXPERIMENTAL
Intervention: Total volume of physical activity (measured in MET-min x wk(-1))
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intensity of physical activity
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Total volume of physical activity
Number of subjects: 34
Study: 9596235

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) loading infusion of 16 mmol followed by 65 mmol over 24 hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) loading infusion of 12 mmol followed by 65 mmol over 24 hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (MgSO4) loading infusion of 8 mmol followed by 65 mmol over 24 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8883720

Group type: EXPERIMENTAL
Intervention: HI group (high electrosurgical current intensity)
Number of subjects: 38

Group type: COMPARATOR
Intervention: LO group (low electrosurgical current intensity)
Number of subjects: 38
Study: 2649156

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: State-Adjusted Treatment (SAT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Verapamil (in manic inpatients)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Neuroleptics (in manic inpatients)
Number of subjects: 86
Study: 327853

Group type: EXPERIMENTAL
Intervention: Acupuncture (Ho‐Ku)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Codeine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Codeine plus Acupuncture (Ho‐Ku)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31013550

Group type: EXPERIMENTAL
Intervention: Δ9-tetrahydrocannabinol (THC) (8 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: THC + cannabidiol (THC + CBD) (8 + 16 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: THC (8 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: CBD (16 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 30447912

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Low-risk comparison group
Number of subjects: 106
Study: 26450601

Group type: EXPERIMENTAL
Intervention: Traditional Mediterranean diet supplemented with extra virgin olive oil (EVOO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Traditional Mediterranean diet supplemented with nuts
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 90
Study: 25872925

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 560

Group type: COMPARATOR
Intervention: BCG vaccination at 6 weeks of age
Number of subjects: 560
Study: 23407746

Group type: EXPERIMENTAL
Intervention: Social validation for killing bugs (manipulated through confederate actions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social invalidation for killing bugs (manipulated through confederate actions)
Number of subjects: 0
Study: 21294997

Group type: EXPERIMENTAL
Intervention: 5 mg loxapine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 10 mg loxapine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 19348600

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% added to timolol 0.5%
Number of subjects: 146

Group type: COMPARATOR
Intervention: Brinzolamide 1% added to timolol 0.5%
Number of subjects: 146
Study: 18246742

Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment
Number of subjects: 114
Study: 15264734

Group type: EXPERIMENTAL
Intervention: Tuohy needle (Group N, n=31)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Epidural catheter (Group C, n=28)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Tuohy needle (Group NE, n=10)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Epidural catheter (Group CE, n=10)
Number of subjects: 79
Study: 11565669

Group type: EXPERIMENTAL
Intervention: 20-g albumin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2-g albumin
Number of subjects: 60

Group type: COMPARATOR
Intervention: No albumin
Number of subjects: 60
Study: 9610448

Group type: EXPERIMENTAL
Intervention: Diffractive bifocal IOL
Number of subjects: 221

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Bilateral diffractive bifocal IOL
Number of subjects: 221
Study: 7922833

Group type: EXPERIMENTAL
Intervention: Atropine sulphate 0.04 mg/kg followed by propranolol 0.2 mg/kg
Number of subjects: 37
Study: 3074299

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily (Group B)
Number of subjects: 30
Study: 29233669

Group type: EXPERIMENTAL
Intervention: Voice-based note creation system
Number of subjects: 709
Study: 28350796

Group type: EXPERIMENTAL
Intervention: iCST (75, 30‐min sessions)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: iCST
Number of subjects: 356

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 356
Study: 26725385

Group type: EXPERIMENTAL
Intervention: Femoral and sciatic nerve block (SF) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral nerve block (F) group
Number of subjects: 60
Study: 24461613

Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg)
Number of subjects: 3444

Group type: COMPARATOR
Intervention: Tiotropium (18 μg)
Number of subjects: 3444
Study: 21722501

Group type: EXPERIMENTAL
Intervention: F60027 (Structovial)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Hylan G-F20 (Synvisc)
Number of subjects: 276
Study: 19451093

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg b.i.d. for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 0
Study: 16939509

Group type: EXPERIMENTAL
Intervention: High-velocity varied-resistance training (HV)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Slow to moderate-velocity constant-resistance training (CT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined once weekly high-velocity varied-resistance and once weekly gymnasium-based functional training (CB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No training (Control - CO)
Number of subjects: 100
Study: 16335645

Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 vaginal tablets (n = 75)
Number of subjects: 147

Group type: COMPARATOR
Intervention: 50 mL intracervical Foley catheter (n = 72)
Number of subjects: 147
Study: 11046104

Group type: EXPERIMENTAL
Intervention: xemilofiban (10 or 20 mg three times daily)
Number of subjects: 7232

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7232

Group type: EXPERIMENTAL
Intervention: xemilofiban
Number of subjects: 7232
Study: 9505816

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin at a concentration of 5 IU/ml added to infusion fluid (n = 55)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No heparin (control group, n = 56)
Number of subjects: 111
Study: 1447436

Group type: EXPERIMENTAL
Intervention: Infrared tympanic membrane (TM) thermometry
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard electronic oral (PO) thermometry
Number of subjects: 82

Group type: COMPARATOR
Intervention: Rectal (R) thermometry
Number of subjects: 82
Study: 3903906

Group type: EXPERIMENTAL
Intervention: Pivampicillin, 700 mg twice daily for seven days
Number of subjects: 289

Group type: COMPARATOR
Intervention: Metronidazole, 500 mg twice daily for seven days
Number of subjects: 289
Study: 31329901

Group type: EXPERIMENTAL
Intervention: CT SAT density measurement
Number of subjects: 54
Study: 30104371

Group type: EXPERIMENTAL
Intervention: Intermittent social influence
Number of subjects: 3

Group type: COMPARATOR
Intervention: Constant social influence
Number of subjects: 3

Group type: COMPARATOR
Intervention: No social influence
Number of subjects: 3
Study: 29336426

Group type: COMPARATOR
Intervention: Weekly oral methotrexate only (Group I)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Weekly oral methotrexate plus soak PUVAsol therapy twice weekly for three months (Group II)
Number of subjects: 54
Study: 24604886

Group type: EXPERIMENTAL
Intervention: Oat-enriched diet (OAT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard dietary advice (SDA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Healthy test meal (postprandial response)
Number of subjects: 22
Study: 22377251

Group type: EXPERIMENTAL
Intervention: CT colonography (CTC)
Number of subjects: 490
Study: 20629598

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg LD/10 mg MD)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Prasugrel (30 mg LD/7.5 mg MD)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Prasugrel (30 mg LD/5 mg MD)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg LD/75 mg MD)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Prasugrel (all dosing regimens)
Number of subjects: 715
Study: 17959953

Group type: EXPERIMENTAL
Intervention: Oral melatonin 5 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 15865226

Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for 1 year (group 1a, n=19)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Untreated controls (group 1b, n=18)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inactive carriers (group 2, n=18)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment (group 1a)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Observation of untreated patients (group 1b and group 2)
Number of subjects: 55
Study: 12464959

Group type: EXPERIMENTAL
Intervention: Peanut protein (various doses)
Number of subjects: 26
Study: 9651635

Group type: EXPERIMENTAL
Intervention: Prompted physician's advice and individual relapse prevention counseling during pregnancy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual physician advice
Number of subjects: 0
Study: 7644961

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 209

Group type: COMPARATOR
Intervention: Manipulation mimic
Number of subjects: 209

Group type: COMPARATOR
Intervention: Back education program
Number of subjects: 209
Study: 2635231

Group type: EXPERIMENTAL
Intervention: Short rating time group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Long rating time group
Number of subjects: 49
Study: 364210

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate
Number of subjects: 51

Group type: COMPARATOR
Intervention: Flumetasone pivalate
Number of subjects: 51
Study: 31535394

Group type: EXPERIMENTAL
Intervention: Early trophic enteral nutrition (EN); median 384 kcal received while on vasopressors.
Number of subjects: 31

Group type: COMPARATOR
Intervention: No enteral nutrition (no EN); median 0 kcal received while on vasopressors.
Number of subjects: 31
Study: 31103412

Group type: EXPERIMENTAL
Intervention: Nintedanib (200 mg twice daily)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 458
Study: 28380494

Group type: EXPERIMENTAL
Intervention: Accelerated up-dosing regimen (0.1-0.3-0.5 mL at weekly intervals)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional up-dosing regimen (0.05-0.1-0.2-0.3-0.4-0.5 mL at weekly intervals)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Both regimens (Accelerated and Conventional)
Number of subjects: 123
Study: 25600249

Group type: EXPERIMENTAL
Intervention: 6-month aftercare programme (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (n = 25)
Number of subjects: 50
Study: 23490040

Group type: EXPERIMENTAL
Intervention: Double Kissing (DK) Crush
Number of subjects: 419

Group type: COMPARATOR
Intervention: Culotte Stenting
Number of subjects: 419
Study: 21888993

Group type: EXPERIMENTAL
Intervention: Dead Space Loading (DSL) 500 ml
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 11
Study: 19587069

Group type: EXPERIMENTAL
Intervention: Community-based recruitment through partnerships with local clinics
Number of subjects: 155

Group type: COMPARATOR
Intervention: Academic site recruitment
Number of subjects: 155
Study: 17033207

Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (rEPO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no rEPO)
Number of subjects: 30
Study: 14730255

Group type: EXPERIMENTAL
Intervention: Penumbral imaging using MRI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DWI and PWI parameters
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100